Three side-chain analogues of cholecalciferol (vitamin D3) Two of the better understood physiological responses of animals to cholecalciferol (vitamin D3), namely the stimulation of intestinal absorption of calcium and increased mobilization of calcium from bone, are known to result from the direct action of the hormone la,25(OH)2D3, the product of two successive hydroxylations of vitamin D catalysed by mixed-function oxygenases, of which one (at C-25) occurs primarily in the liver, the other (at C-1) exclusively in the kidney (DeLuca & Schnoes, 1976 ). For C-1 hydroxylation, the key step of this metabolic activation of vitamin D, 25(OH)D3 serves as the normal precursor in vivo, and, since cholecalciferol itself is not a substrate for the kidney 1-hydroxylase (Gray et al., 1972) , it appears that the side-chain C-25 hydroxy group is a necessary prerequisite for subsequent introduction of the ring-A hydroxy-group function. This information suggests that inhibitors of 25-hydroxylation that possess no intrinsic biological activity should be effective antagonists of vitamin D activation, and consequently, of vitamin D action. As (Fig. 1) feature a blocked C-25 position, but otherwise normal vitamin D carbon skeleton, a structural combination designed to prevent direct hydroxylation by the cholecalciferol 25-hydroxylase while preserving high affinity for the active site of the enzyme. Failure of these analogues to be 25-hydroxylated should in turn prevent subsequent C-1 hydroxylation and thus assure the absence of a vitamin D-like biological response to the compounds. We have shown previously that 25(N)D3, a biologically inactive analogue, does indeed inhibit the 25-hydroxylation of cholecalciferol in vivo, and does antagonize the physiological action of cholecalciferol (Onisko et al., 1979a) . We report here that the other three analogues, 25(F)D3, A24-D3 and A25-D3, although capable of inhibiting the cholecalciferol 25-hydroxylase, are not vitamin D antagonists, because they possess intrinsic biological activity. In the case of the two dehydro compounds, this activity results from their conversion in vivo, in low yield, to I a,25(OH)2D3, whereas the biological responses elicited by 25(F)D3 are a consequence of its metabolism to 1 a-hydroxy-25-fluorocholecalciferol. 
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Abbreviations used: 1 a,25(OH)2D3, 1 a,25-dihydroxycholecalciferol; 25(OH)D3, 25-hydroxycholecalciferol; 25(N)D3, 25-azacholecalciferol; 25(F)D3, 25-fluorocholecalciferol; A&24-D3, 24-dehydrocholecalciferol; A25-D3, 25-dehydrocholecalciferol; h.p.l.c., high-pressure liquid chromatography. Vol. 182 a test of this concept, we prepared four side-chainmodified vitamin D compounds, namely 25(N)D3, 25(F)D3, A24-D3 and A25-D3, conceived as substrate analogues of the cholecalciferol 25-hydroxylase. These synthetic analogues ( Fig. 1 ) feature a blocked C-25 position, but otherwise normal vitamin D carbon skeleton, a structural combination designed to prevent direct hydroxylation by the cholecalciferol 25-hydroxylase while preserving high affinity for the active site of the enzyme. Failure of these analogues to be 25-hydroxylated should in turn prevent subsequent C-1 hydroxylation and thus assure the absence of a vitamin D-like biological response to the compounds. We have shown previously that 25(N)D3, a biologically inactive analogue, does indeed inhibit the 25-hydroxylation of cholecalciferol in vivo, and does antagonize the physiological action of cholecalciferol (Onisko et al., 1979a) . We report here that the other three analogues, 25(F)D3, A24-D3 and A25-D3, although capable of inhibiting the cholecalciferol 25-hydroxylase, are not vitamin D antagonists, because they possess intrinsic biological activity. In the case of the two dehydro compounds, this activity results from their conversion in vivo, in low yield, to I a,25(OH)2D3, whereas the biological responses elicited by 25(F)D3 are a consequence of its metabolism to 1 a-hydroxy-25-fluorocholecalciferol. Napoli et al., 1978) . Preparation of 24-dehydrocholecalciferol and 25-dehydrocholecalciferol To a solution of 25(OH)D3 3-acetate (53mg) in 3.5ml of pyridine, cooled to ice-bath temperature, phosphorus oxychloride (350mg) was added dropwise with stirring. The ice bath was removed, and stirring was continued at ambient temperature for 1.0h. The reaction was stopped by cooling to 0°C, adding 5ml of water dropwise and diluting with 30ml of benzene. The organic layer was separated, washed with 5% (v/v) HCl (4x lOml), 4% NaHCO3 and saturated NaCl (10 ml). After drying the material over Na2SO4, the solvent was evaporated and the residue was applied to a 70g (1.2cmx75cm) column of silica gel containing 10 % (w/w) AgNO3. (Onisko et al., 1977) . This involved selective acetylation (acetic anhydride/ pyridine) of 25(OH)[3-3H]D3 (1.5mg, 3OCi/mol), fluorination of the resulting 3fi-acetate with diethylaminosulphur trifluoride (in dichloromethane for 15min at -78°C), hydrolysis (KOH/methanol) followed by purification by t.l.c. (silica-gel plate 750pm thick, 30 % ethyl acetate/Skellysolve B). The synthetic product showed a u.v.-absorption maximum at 265 nm (in ethanol). A specific radioactivity of 32Ci/mol and an overall yield from 25(OH)D3 of and a flow rate of 1.5 ml/min of propan-2-ol/hexane (1: 99, v/v). Solvents were evaporated from the column fractions (0.5 ml) and the residues were redissolved in toluene-based radioactivity-counting solution {2g of PPO [2,5-diphenyloxazole] Table 1 below) was measured by extraction of the serum by using the method of Bligh & Dyer (1959) , chromatography of the extract on Sephadex LH-20 (Holick & DeLuca, 1971 ) and analysis of the column fractions by liquid-scintillation counting.
Intestinal-calcium-transport and bone-calciummobilization assays. Rats maintained as described above were divided randomly into groups of six animals, then dosed intrajugularly under light ether anaesthesia. Doses (see Table 2 below for material and amount) were prepared by dissolving the appropriate substance in ethanol (0.05ml/rat). The dose protocol (compound, amount, Tables 2 and  3 below. The animals were killed by decapitation and their blood and duodena were obtained. Bonecalcium mobilization was determined by measuring serum calcium concentrations; 0.1 ml portions of serum were diluted with 1.9ml of 0.1 % aqueous LaCl3, and calcium was measured by atomic absorption with a Perkin-Elmer model 403 instrument. Intestinal calcium transport was determined by using the everted-gut-sac technique of Martin & DeLuca (1969) . For 45Ca radioactivity counting, portions from the serosal and mucosal media were spotted on filter-paper discs, dried, and placed in 20ml counting vials containing 10ml of toluene counting solution.
time) is detailed in
Metabolism of A24-D3 and A25-D3. Vitamin Ddeficient rats (see above) were divided into groups of three animals, then dosed intrajugularly under ether anaesthesia with either ethanol (0.05 ml) or ethanol (0.05 ml) containing A'4-D3 (50,ug) , A25-D3 (50,pg) or vitamin D3 (50ng). At 20h after dosing, the animals were killed by jugular exsanguination under light ether anaesthesia. The collected blood from rats of the same group was pooled, and the resulting serum was analysed for 1 a,25(OH)2D3 content by the method of Eisman et al. (1976 Serum samples were extracted as described by Bligh & Dyer (1959) ; intestinal homogenates were extracted by the method of Lund & DeLuca (1966) . The extracts were chromatographed on a column (2cm x 28 cm) of (Holick & DeLuca, 1971 (Table 3) assume that the total serum volume represents 3 % of the body weight.
Selected radioactive peaks from the Sephadex LH-20 columns were further analysed by h.p.l.c. on a 0.4cm x 30cm column (uPorasil; Waters), which was operated at 3.45 MPa (500lb/in2). This gave a flow rate of 2.0 ml of propan-2-ol/hexane (1:19, v/v)/min. Appropriate Sephadex LH-20 column fractions (see Fig. 3 ) were pooled, solvents were evaporated, the residues were redissolved in column solvent, and a mixture of standard fluorinated analogues was added before injection. Fractions (50, 0.5ml each) were collected after each sample injection; each was analysed for 3H as for the Sephadex LH-20 column fractions. H.p.l.c. recovery of radioactivity ranged from 80 to 90%.
Results
The ability of 25(F)D3, A24-D3 and A25-D3 to inhibit the 25-hydroxylation of cholecalciferol in vivo is demonstrated by the data of (Table 2) . At lower doses (5,pg, Table 3) only 25(F)D3 significantly elevated serum calcium, whereas intestinal calcium transport was stimulated by all three compounds. At the lowest dose (0.5 ug, Table 3 ) no significant bone response was observed, and only 25(F)D3 exhibited a moderate activity in intestine. The magnitude of the responses caused by 25(F)D3, A24-D3 and A25-D3, when compared with that of a physiological dose ofcholecalciferol (0.05 pg) establishes the potency in vivo of 25(F)D3 to be 100-300 times lower than that of cholecalciferol, whereas A24-D3 and A25-D3 are estimated to be -300-1000 times less active than cholecalciferol.
The biological activity of the two dehydro compounds is accounted for by their conversion, in vivo, into 1 a,25(OH)2D3. At 20h after administration of a 50pg dose of A24-D3 or A25-D3 to vitamin D-deficient rats, the concentration of 1 c,25(OH)2D3 in serum was 1 I0pg/ml and 180pg/ml respectively (Table 4) . Under these conditions, untreated (ethanol-dosed) control animals had undetectable (<3 pg/ml of serum) amounts of circulating 1 a,25(OH)2D3, whereas in rats given cholecalciferol (0.05,ug) serum concentrations of 1 cx,25(OH)2D3 reached values of 300pg/ml (Table 4) . Although the substance produced in vivo from both A2'-D3 and A25-D3 was not isolated and specifically characterized, it is safe to conclude that it is indeed 1 a,25(OH)2D3, since the assay used (Eisman et al., 1976) requires (1) co-migration with 1 a,25(OH)2D3 on Sephadex LH-20 and h.p.l.c., and (2) the displacement of bound 1 a,25(OH)2[3H]D3 from its highly specific intestinal receptor (Kream et al., 1977) . The relatively higher potency in vivo of 25(F)D3 (as compared with A24-D3 and A25-D3; see Tables 2 and  3) suggested that this analogue might also be subject to metabolic activation. To investigate this question directly we prepared 3H-labelled 25(F)D3 by fluorination of 25-hydroxy[3a-3H]cholecalciferol 3-acetate. Synthetic 25-fluoro[3-3H]cholecalciferol was characterized by its u.v.-absorption spectrum (irax. 265 nm) and co-mrgration with authentic 25(F)D3 on analytical h.p.l.c. (see Fig. 2 ). These data and its known method of preparation (Onisko et al., 1977) assure the authenticity and purity of the radioactively labelled substance.
When the 25-fluoro[3-3H]cholecalciferol (15,g/ animal) was administered to vitamin D-deficient rats, and serum and intestinal extracts were chromatographed on Sephadex LH-20, two minor radioactive peaks more polar than 25(F)D3 (peak F-I) were observed, namely peaks F-Il and F-III, as shown in (Fig. 4) . Chromatography of peak F-III from an intact rat resulted in resolution oftwo components, Quantitative distribution data for peaks F-I and F-III derived from the Sephadex LH-20 column profiles are summarized in Table 5 . (Peak F-II could not be quantified accurately because it represents a small shoulder after the large F-I peak.) In intact animals, the concentrations of 25(F)D3 (peak F-I) in both serum and intestine decreased with time; amounts of peak-F-Ill material remained essentially constant. The same is true for anephric animals, but the significantly higher amounts of 25(F)D3 in intestine and serum and at both time points are noteworthy. Peak-F-Ill material never amounted to more than 0.33% of the dose, and the quantitative differences between normal and anephric animals are slight. It (Table 2 ). The demonstration that the analogues possess inherent biological activity (Tables 2 and 3 ) explains and reconciles these seemingly disparate results. Considering the structures of the three compounds it appeared reasonable to assume that their activity was not the result of direct cellular action, but that, like cholecalciferol itself, they were subject to metabolism to more active forms. For the case of the two dehydro analogues, A24-D3 and A25-D3, we have shown that the active form is 1 a,25(OH)2D3 (Table 4) .
The required conversion in vivo of the dehydro analogues into 1 a,25(OH)2D3 is obviously a lowyield and inefficient process, as evidenced by the low potency of either A24-D3 or A25-D3 compared with cholecalciferol (Table 3) , but the amounts of 1 a,25(OH)2D3 accumulating in blood in response to analogue administration (Table 4) are quite adequate to account for their biological activity. We presume that metabolism of A24-D3 and A25-D3 involves an initial reduction to cholecalciferol, followed by the normal two-step hydroxylation sequence. Direct reduction of the side-chain double bond of A24-D3 and A25-D3 is certainly conceivable and, based on analogous conversions, probably to be expected. Desmosterol is reduced to cholesterol by the rat liver sterol A24-reductase (Avigan & Steinberg, 1961) . The enzyme has broad substrate specificity, since lanosterol is reduced at a rate comparable with that observed for desmosterol (Avigan et al., 1963) . Cellfree liver preparations are also capable of converting 25-dehydrocholesterol to cholesterol, but at a rate much slower than that for desmosterol (Steinberg & 1979 Avigan, 1969 (Napoli et al., 1978) . Although the yield of 1 a(OH)25(F)D3 is low, the amounts of metabolite produced over the time course of the assay (e.g. 7.1 ng/ml of serum after lOh, on the basis of the data of Table 5 and Fig. 4) (Figs. 3 and 4) , are significant contributors to activity; their synthesis in the absence of kidney tissue implies that they are not 1-hydroxylated (an extrarenal 1-hydroxylase for vitamin D compounds has, as yet, not been encountered). Given the importance ofa 1 a-hydroxy function for expression of activity, these unknown metabolites of 25(F)D3 are not expected to induce a significant biological response at the concentrations measured (Table 5, Figs. 3 and 4) . C-1 hydroxylation of 25(F)D3 therefore accounts, at least in large measure, for the biological activity observed for 25(F)D3 and explains its failure to antagonize the action of cholecalciferol, even though 25(F)D3 is by far a more potent inhibitor of the 25-hydroxylation of vitamin D than the known vitamin D antagonist, 25-azacholecalciferol (Onisko et al., 1979a (Gray et al., 1972; Tanaka et al., 1977 ). An electronegative fluorine substituent at C-25 may, of course, render 25(F)D3 a somewhat better substrate than cholecalciferol itself, and this factor, combined with high substrate concentrations (e.g. 50,pg/animal), and possibly a somewhat broader substrate specificity of the rat enzyme, can account for the observed lowyield 1 a-hydroxylation of 25(F)D3. These questions can be addressed directly by comparisons in vitro of the chick and rat I ac-hydroxylase systems.
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